Max Mackenzie Quinn, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Azepines | 2 | 2018 | 329 | 0.260 |
Why?
|
| Triazoles | 2 | 2018 | 904 | 0.210 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 56 | 0.150 |
Why?
|
| Drug Synergism | 2 | 2018 | 1760 | 0.130 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 13586 | 0.130 |
Why?
|
| Acrylamides | 1 | 2018 | 261 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 1767 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 448 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 354 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 565 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 2956 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 454 | 0.100 |
Why?
|
| Thiophenes | 1 | 2017 | 570 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2018 | 864 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2017 | 887 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2018 | 1094 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5432 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 5704 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3612 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2211 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2603 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5505 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 5804 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 10266 | 0.050 |
Why?
|
| Proteins | 1 | 2018 | 6009 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2018 | 3623 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 17142 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11878 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6395 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9419 | 0.040 |
Why?
|
| Mutation | 3 | 2018 | 30237 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13677 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 10478 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 669 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 825 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 483 | 0.030 |
Why?
|
| Mice | 5 | 2018 | 82049 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 646 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 2394 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1105 | 0.020 |
Why?
|
| Animals | 6 | 2018 | 169285 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1495 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 6124 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 3428 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2048 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 18349 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 22371 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6316 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2830 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2018 | 3048 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9561 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 7452 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14488 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 9527 | 0.010 |
Why?
|
| Humans | 5 | 2018 | 768171 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 65379 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36741 | 0.010 |
Why?
|
| Female | 2 | 2018 | 397187 | 0.000 |
Why?
|
| Middle Aged | 1 | 2018 | 223487 | 0.000 |
Why?
|
| Male | 1 | 2018 | 364731 | 0.000 |
Why?
|